{"id":"NCT00454584","sponsor":"Centocor, Inc.","briefTitle":"An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis","officialTitle":"A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-03","primaryCompletion":"2008-01","completion":"2009-01","firstPosted":"2007-03-30","resultsPosted":"2012-11-21","lastUpdate":"2012-11-21"},"enrollment":903,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"CNTO 1275 45 mg","otherNames":[]},{"type":"DRUG","name":"CNTO 1275 90 mg","otherNames":[]},{"type":"DRUG","name":"Etanercept 50 mg","otherNames":[]}],"arms":[{"label":"CNTO 1275 45 mg","type":"EXPERIMENTAL"},{"label":"CNTO 1275 90 mg","type":"EXPERIMENTAL"},{"label":"Etanercept 50 mg","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy and safety of CNTO 1275 to etanercept in patients with moderate to severe plaque psoriasis.","primaryOutcome":{"measure":"Number of Participants Achieving a Greater Than or Equal to 75 Percentage Improvement From Baseline in Psoriasis Area and Severity Index (PASI 75) Score at Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Group I: Etanercept","deltaMin":197,"sd":null},{"arm":"Group II: Ustekinumab 45 mg","deltaMin":141,"sd":null},{"arm":"Group III: Ustekinumab 90 mg","deltaMin":256,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG000 vs OG001","p":"0.012"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["30739254","20071701"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":347},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Back pain","Injection site erythema"]}}